[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma].
27 patients (24 male und 3 female) with inoperable non-small-cell lung cancer were treated with combined mitomycin C, vindesine, and ifosfamide. The performance status of all patients was over 70%. 20 patients had extensive disease, 7 limited disease. The most frequent histology was squamous cell carcinoma found in 20 patients. Only 3 patients had large cell carcinoma and 4 patients adenocarcinoma. 2 complete (7.7%) and 9 partial remissions (34.6%) were achieved. 3/26 (11.5%) patients showed a minor response. In 7/26 patients (26.9%) there was no change, 5/26 (19.2%) showed progressive disease. Because of the short observation time, no deductions regarding the duration of remission and survival time of the patients can be made. The toxicity of the regimen was relatively mild. In particular, the subjective gastro-intestinal symptoms occurred only in 50% of our patients. The hematological toxicity was acceptable. Also the renal toxicity did not pose problems. Considering an exact lung function analysis with diffusing capacity and spirometric data, we found an unexpectedly high proportion of pulmonary toxicity in about 30%, but clinically obvious in only 10% of patients. According to the remission rates, this regimen is comparable to combinations with cisplatin and appears to have much less toxicity.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D014751:Vindesine / Q000008:administration & dosage* / Q000009:adverse effects
D008937:Mitomycins; D016685:Mitomycin; D014751:Vindesine; D007069:Ifosfamide
Chemotherapie mit Mitomycin C, Vindesin und Ifosfamid in der Behandlung des inoperablen nicht-kleinzelligen Bronchialkarzinoms.